PFIZER

Industry: Pharmaceutical
Headquarters: New York
Employees globally: 88,000
Footprint: Operations in nearly 70 countries globally
Global revenue: €54.1 billion (FY23)
European T&E spend 2023: €78 million, of which around €26 million was spent on air travel
Global T&E spend 2023: €416 million
Primary TMC partner: BCD Travel
Primary booking tool: Concur
Primary travel risk management provider: Everbridge
Primary payment provider: American Express
Travel programme insights: Around half of the company’s travel activity is for internal purposes; it does not expect volumes to return to pre-pandemic levels for several years. It has a single global policy covering more than 80 per cent of travel spend.
Sustainability targets: Pfizer is working towards net zero by 2040 which includes a goal of a 95 per cent reduction in Scope 1 and 2 emissions and a 90 per cent reduction in Scope 3 emissions compared to 2019. As part of that commitment, it has pledged to reduce its business travel emissions by 25 per cent by 2025 from a 2019 baseline.
Travel-related sustainability actions: Pfizer says it has implemented tools to help business travellers make informed decisions about travel options, including digital tools designed to
limit travel and steer employees towards preferred carriers that are advancing their GHG reduction targets.
Sustainability reporting: According to its 2023 impact report, Pfizer’s travel-related GHG emissions were 55 per cent lower than its 2019 baseline. It estimates that bookings outside of its ‘travel system’ contribute ten per cent of its overall travel emissions. In 2023 its business travel activity was responsible for 173,000 tCO2e, around 11 per cent of its overall company emissions. Its business travel emissions in 2023 were almost twice that of 2022 as business travel recovered rapidly but was less than half of its 2019 baseline figure, at 384,000 tCO2e.